H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint

H.C. Wainwright analyst Joseph Pantginis notes that Esperion has announced its Phase 3 CLEAR Outcomes trial evaluating NEXLETOL met its primary endpoint. Patients experienced a statistically significant risk reduction in MACE-4 after administration of 180 mg/day NEXLETOL compared to placebo. Pantginis expects the announcement to have a positive impact on the stock ahead of the full data, though could see increased volatility in the interim as investors weigh the news. He looks forward to the data at a major medical conference in Q1 2023. The analyst reiterates a Buy rating on the shares with a price target of $22.